Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index; 38 of the 56 sources its claims cite were checked for support.

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412

Open access

Published version of a preprint

Abstract

Purpose: In many cancers, nivolumab in combination with ipilimumab improves response rates compared with either agent alone, but the combination has not been evaluated in childhood cancer. We conducted a phase I/II trial of nivolumab plus ipilimumab in children and young adults with recurrent/refractory solid tumors. Patients and Methods: ADVL1412, Part C assessed safety of nivolumab plus ipilimumab at two dose levels (DL): DL1 1 mg/kg of each drug and DL2 3 mg/kg nivolumab plus 1 mg/kg ipilimumab. Part D evaluated response at the recommended phase II dose (RP2D) in Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Part E tested DL3 (1 mg/kg nivolumab plus 3 mg/kg ipilimumab) in Ewing sarcoma and rhabdomyosarcoma. Tumor response was measured using RECIST v1.1. Pharmacokinetics and PD-L1 expression on archival tissues were assessed. Results: Fifty-five eligible patients enrolled. Based on safety, tolerability, and similar drug exposure to the same doses administered in adults, DL2 was defined as the pediatric RP2D. Among 41 patients treated at the RP2D, 2 patients experienced dose-limiting toxicities during cycle 1, and 4 patients experienced toxicities beyond that period. Two patients had clinically significant sustained partial responses (1 rhabdomyosarcoma, 1 Ewing sarcoma) and 4 had stable disease. Among 8 patients treated at DL3, 3 dose-limiting toxicities (DLT) occurred, all immune-related adverse events; no objective responses were observed. Conclusions: The RP2D of nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) is well tolerated in children and young adults with solid tumors and shows some clinical activity. Increased dose of ipilimumab (3 mg/kg) plus nivolumab (1 mg/kg) was associated with increased toxicity without clinical benefit.

Overview

CoChat Summary

TL;DR

In children and young adults with relapsed/refractory solid tumors, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg was defined as the pediatric RP2D and showed tolerable toxicity with limited clinical activity. A higher ipilimumab dose (3 mg/kg with nivolumab 1 mg/kg) was associated with increased immune-related toxicity and no objective responses.

Key findings

  • Fifty-five eligible patients enrolled; 53 were evaluable for DLT. DL2 (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg) was defined as the pediatric RP2D based on safety, tolerability, and similar drug exposure to the same doses in adults. Among 41 patients treated at the RP2D, 2 had Cycle 1 DLTs (grade 3 creatinine increase; grade 4 pleural effusion), and additional DLTs beyond Cycle 1 occurred in 2 Part C patients and 4 Part D patients.
  • At the RP2D, 2 patients had confirmed partial responses (1 alveolar rhabdomyosarcoma, 1 Ewing sarcoma) and 4 had stable disease (2 rhabdomyosarcoma, 1 myofibroblastic tumor, 1 nasopharyngeal carcinoma). Both responders remained alive without disease progression at 36-month follow-up. No activity was observed in the osteosarcoma cohort.
  • Among 8 patients treated at DL3 (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg), 3 DLTs occurred (37.5%), all immune-related adverse events; no objective responses were observed in rhabdomyosarcoma (n=3) or Ewing sarcoma (n=4).
  • Of 49 patients with archival tumor tissue evaluable for PD-L1, only 7 (14%) had any PD-L1 staining; there was no clear relationship between PD-L1 expression and clinical response or toxicity.

Methods

  • ADVL1412 Parts C–E: Part C was dose finding at DL1 (1 mg/kg nivolumab plus 1 mg/kg ipilimumab) and DL2 (3 mg/kg nivolumab plus 1 mg/kg ipilimumab); Part D tested DL2 in disease-specific expansion cohorts for rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma using a Simon optimal two-stage design; Part E tested DL3 (1 mg/kg nivolumab plus 3 mg/kg ipilimumab) in rhabdomyosarcoma and Ewing sarcoma.
  • Treatment was given Day 1 every 21 days for four cycles, followed by single-agent nivolumab 3 mg/kg every 14 days. Response was assessed by RECIST v1.1 with central review; toxicity was graded by CTCAE v5.0; pharmacokinetics and PD-L1 immunohistochemistry on archival tissue were assessed.
  • The Simon design assumed a true response rate of 5% versus 25%, with type I error 0.07, power 0.88, and expected sample size of 14 with 60% probability of early termination.

Limitations

  • Stated: evaluation was limited to common childhood sarcomas (rhabdomyosarcoma, Ewing sarcoma, osteosarcoma), so performance in other childhood cancer histologies is not addressed; enrollment of very young children was limited; PD-L1 IHC was largely performed on diagnostic specimens, so PD-L1 expression at the time of immune checkpoint therapy is unknown; tumor neoantigen burden could not be evaluated; pre-treatment biopsies and additional correlative studies are needed.
  • Evident from the text: this was a single-arm, non-randomized trial with small disease-specific cohorts; Part E was closed early after the DL3 stopping rule was triggered, limiting efficacy assessment; no expansion cohort met response criteria to proceed to stage 2; patients received a median of 2 cycles, which may limit comparisons of toxicity and response with adult regimens.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-22-2164

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

22 Valid · 0 Not valid · 5 Not checked · 94 Own results and interpretations

51 more claims · 7 with their cited sources checked

Create a free account to see all 121 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 29
  • It may state two separate claims as one. 37
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 47 references

Cited by

See all 75

Metadata

Authors
Davis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L.
Affiliations
  • Stanford Medicine (US)
  • St. Jude Children's Research Hospital (US)
  • Mayo Clinic (US)
  • Children's Oncology Group (US)
  • Baylor College of Medicine (US)
  • Harvard University (US)
  • University of Minnesota (US)
Corresponding author
Davis, Kara L.
Venue
Clinical Cancer Research
Published
2022-10-03
Volume
28
Issue
23
Pages
5088-5097
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4300688643
Cited by
75
References
47
Citations by year
2026: 16 · 2025: 31 · 2024: 18 · 2023: 9 · 2022: 1
FWCI
6.17
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
  • Bristol-Myers Squibb (CA209-070)
  • National Institutes of Health (CA228823, 5P30CA124435, P30 CA015083)
  • Cookies for Kids' Cancer Foundation (NA)
  • Parker Institute for Cancer Immunotherapy
  • Virginia and D.K. Ludwig Fund for Cancer Research
  • Stanford Maternal and Child Health Research Institute
  • National Institute of General Medical Sciences (T32GM 08685)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
nivolumab, ipilimumab, immune checkpoint inhibitors, combination immunotherapy, pediatric solid tumors, relapsed/refractory cancer, children and young adults, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, dose-limiting toxicity, immune-related adverse events, PD-L1 expression, pharmacokinetics, recommended phase 2 dose
MeSH terms
Ipilimumab, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Child, Humans, Neoplasm Recurrence, Local, Rhabdomyosarcoma, Sarcoma, Ewing, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-2164
The paper
Davis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L. (2022). A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-2164

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.